GlassScriptPhysician profile
Alan T Glass
NPI 1124015318
$17,535.52
in general payments reported to CMS, 2019-2025
37 companies · $3,286 in 2025
The $3,286 reported for 2025 was more than what 85% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $1,412 · 2021: $1,848 · 2022: $3,556 · 2023: $3,572 · 2024: $3,211 · 2025: $3,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,054.66 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $1,790.23 | 2020-2022 | |
| Genzyme Corporation | $1,626.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,375.60 | 2020-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $1,092.24 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $1,067.06 | 2022-2024 | Vtama |
| Abbvie INC. | $1,023.77 | 2020-2025 | |
| Incyte Corporation | $1,004.65 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $907.45 | 2020-2025 | Oracea, Epsolay, Aklief |
| Novartis Pharmaceuticals Corporation | $883.95 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $820.32 | 2020-2025 | Cabtreo, Jublia |
| Pfizer INC. | $816.81 | 2020-2025 | |
| Botanix Sb INC | $712.14 | 2025 | Sofdra |
| Amgen INC. | $584.58 | 2019-2025 | Otezla, Otezla |
| Journey Medical Corporation | $539.22 | 2020-2024 | |
| Lilly USA, LLC | $484.17 | 2020-2025 | Taltz, Olumiant, Ebglyss |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $399.04 | 2020-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $353.61 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $264.21 | 2020-2021 | |
| Merz North America, INC. | $243.24 | 2022-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $239.22 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Celgene Corporation | $183.56 | 2019 | |
| Allergan, INC. | $162.20 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $145.24 | 2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $144.00 | 2021-2022 | |
| Almirall LLC | $143.58 | 2020-2024 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $139.19 | 2022-2023 | Sotyktu |
| Dermira, INC. | $60.33 | 2019-2020 | |
| Encore Dermatology INC. | $54.84 | 2019-2020 | |
| Ucb, INC. | $50.12 | 2021-2024 | Bimzelx |
| Sebela Pharmaceuticals INC. | $46.34 | 2023 | Naftin, Pramosone |
| Janssen Biotech, INC. | $40.81 | 2020-2025 | Tremfya |
| Promius Pharma LLC | $37.81 | 2019 | |
| Glenmark Therapeutics INC. | $31.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.82 | 2024 | Ycanth |
| Organon LLC | $16.61 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $15.16 | 2019 | |
| Mission Pharmacal Company | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.